CKD
Conditions
Interventions
olmesartan 20mg to 40mg/day
olmesartan 20mg to olmesartan 20mg+amlodipine 5mg/day
olmesartan 20mg to olmesartan 20mg+benidipine 4mg/day
olmesartan 20mg to olmesartan 20mg+azelnidipine 16mg/day
Sponsors
Department of Cardio-Renal Medicine and Hypertension, Nagoya City University Graduate School of Medical Sciences
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) CKD, age ≥16y 2) preceding treatment with olmesartan (20mg/day) at least 8 weeks before enrollment 3) office BP ≥130/80 mmHg at 2 different visits 4) documented informed concent
Exclusion criteria
Exclusion criteria: 1) preceding treatment with CCB 4-week before enrollment 2) contra indications for study medications 3) presence/possibility for pregnancy/lactation 4) HbA1c ≥9.0% 5) GOT >100, or GPT >85 6) endocrine hypertension 7) accelerated or malignant hypertension 8) serious conditions with congestive heart failure, coronary diseases, arrhythmia or systemic diseases 9) any reason for ineligibility suggested by the attending doctor
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Plasma Aldosterone Concentration, urinary potassium/sodium excretion ratio, trans-tubular potassium concentration gradient (TTKG) | — |
Secondary
| Measure | Time frame |
|---|---|
| Serum potassium concentration, sympathetic activity, intrarenal renin-angiotensin system activity, oxidative stress | — |
Countries
Japan
Contacts
Public ContactMichio FUKUDA
Nagoya City University Graduate School of Medical Sciences Department of Cardio-Renal Medicine and Hypertension
Outcome results
None listed